Jubilant Ingrevia Enters Electronics Sector with ₹189.2 Crore Stake in Zettaone Technologies

Date:

Share post:

Jubilant Ingrevia Limited has announced a strategic move to diversify its business portfolio by acquiring a 40% equity stake in Zettaone Technologies for ₹189.2 crore.

The strategic investment marks Jubilant Ingrevia’s formal entry into the high-growth Electronics Development and Manufacturing Services (EDMS) sector. The expansion comes at a pivotal time when India is rapidly accelerating the development of a robust domestic ecosystem for electronics and semiconductor manufacturing.

Through this transaction, Jubilant Ingrevia aims to gain direct exposure to emerging, high-potential technology opportunities by leveraging Zettaone Technologies’ proven capabilities in electronics design, engineering, and manufacturing. The initiative aligns with the company’s broader strategic vision of expanding beyond its traditional operating domains to build diversified revenue streams in high-demand technological industries.

With the rising nationwide push for advanced domestic electronics and local supply chain resilience, the partnership is set to unlock substantial growth synergies and actively contribute to strengthening India’s manufacturing infrastructure.

Written by: Pragna Biswas

Graphics by: Pramit Hazra

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Union Health Ministry Proposes Inclusion of Four Drugs Under Schedule H1 to Tighten Regulatory Oversight

The Ministry of Health and Family Welfare (MoHFW), Department of Health and Family Welfare, has issued a draft...

Amylyx Pharmaceuticals Announces Positive Phase 3 Trial Results for Avexitide, for Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals has announced positive top-line results from its pivotal Phase 3 LUCIDITY trial evaluating avexitide, a first-in-class...

Merck & Moderna’s Personalized mRNA Cancer Vaccine Succeeds in Phase 3 Melanoma Trial

Pharmaceutical giants Merck and Modernarevealed encouraging results from their Phase 3 INTerpath-001 study, testing an individualized mRNA cancer vaccine...

Glenmark Secures U.S. FDA Approval for Flonase®️ Nasal Spray

Glenmark Pharmaceuticals Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New...